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Section I. Emerging viral infections
V. 1.
History of Medical Microbiology Institute
Dóra Szabó
Institute of Medical Microbiology, Semmelweis University, Hungary
The first institutional microbiology scientific work and teaching activity was established in 
1883 by Endre Hőgyes. At that time microbiology and pathophysiology were combined in 
one subject and it was organized in the General Pathophysiology and Bacteriology Institute. 
Due to facility improvements in the Institute the number of students increased to 1200. Endre 
Hőgyes was the head of the Institute for 20 years and during that time scientific and teaching 
activity was maintained. In 1890 Endre Hőgyes founded the Institut Pasteur in Budapest to 
continue scientific work that he had  started in Paris as a colleague of Louis Pasteur. 
In 1948 the Insitute of Bacteriology and Immunity was founded that organized teaching 
and scientific work of microbiology. In 1950 the head of the Institute was Ferenc Faragó and 
our Institute was named as Institute of Microbiology. 
Adenovirus research team was established in 1956 by István Nász. The scientific acitvity 
was financially supported by the Hungarian Academy of Sciences that covered positions in 
the team, participation in congresses and in study tours. Since 1999 our Institute has been 
named as Insitute of Medical Microbiology 
Nowadays, our Institute teaches in three languages (Hungarian, English and German) on 
three Faculties of Semmelweis University namely, Medicine, Dentistry and Pharmacy. Our 
Institute takes part also in organizing courses, workshops in different fields of microbiology. 
Throughout the decades scientific work of our Institute covered bacteriology, virology, mi-
crobiome and prions. In 1988 the Microbiology Museum and Archive has been established 
and maintained by István Nasz, a Full Member of the Hungarian Academy of Sciences. This 
museum demonstrates all the scientific work including all publications of our Institute from 
1948 till today. 
V. 2.
Studies on adenoviruses at the Institute of Microbiology 
Joseph Ongrádi 
Institute of Medical Microbiology, Semmelweis University, Budapest, Hungary 
The Adenovirus Research Group (Institute of Microbiology, Medical University of Buda-
pest) was established by Dr. István Nász (Professor and Head 1974−1994, Member of the 
Hungarian Academy of Sciences) in the mid 1950s. Three subgroups were formed: 1) Studies 
on the fine structure of hexon molecules and their comparison by monoclonal antibodies for 
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gene therapy – Éva Ádám, DPharm, DSc 2) Comparative analysis of type specific DNA – 
György Berencsi MD, PhD, 3) Studies on the clinical significance of adenoviruses in immu-
nomodulation – Gizella Kulcsár MD, DSc. Major trends in immunomodulatory studies were: 
Latent adenovirus infection could be established by using minimal inocula or temperature 
sensitive mutants of HAdV-5 in tissue cultures or mouse lymphocytes. Among several inor-
ganic and organic compounds tested bacterial endotoxin, steroid hormones, prostaglandins 
and indomethacin could reactivate and augment adenovirus replication via cellular secondary 
messenger systems. Lymphocytes carrying latent HAdV-1 and HSV-1 are excreted through 
the gingival sulcus consequently contribute to juvenile periodontitis by decreasing the activ-
ity of phagocytes. In vitro, their TNF-a production parallel to oncogenic potential was shown 
to suppress bactericidal capacity of phagocytes. It was shown that circulating and tumor 
infiltrating lymphocytes frequently express HAdV functions and their immunomodulatory 
effects may contribute to the progression of malignancies of the male urogenital system. Ad-
enovirus research ceased around the Millenium, but has been re-established at the Institute of 
Medical Microbiology since 2010s. As HAdVs are important cofactors in AIDS progression 
and mortality, in the frame of the feline AIDS model AdV serological survey was conducted 
in Europe: nearly 20% of cats were found seropositive. An infectious agent obtained from the 
faces of a cat and identified as the first adenovirus isolate in Felidae worldwide. Its biological 
and molecular and characterizations are in progress.
V. 3.
The Adenovirus Research Group of the Hungarian Academy of 
Sciences, 1995−1998 
Orsolya Dobay 
Institute of Medical Microbiology, Semmelweis University, Hungary
The Semmelweis University − Hungarian Academy of Sciences Adenovirus Research Group 
was grounded and led by Professor István Nász. When I started working in the Institute of 
Medical Microbiology in 1995, I became part of this group and had the opportunity to join the 
ongoing research. In the frame of a veterinary project, we examined the Adenovirus infection 
in cats. First, we tested 100 cat sera from the Czech Republic, using HAdV-1 hexon antigen. 
We detected 25% seropositivity, which was higher in females, in very young or very old cats, 
and cats with respiratory or GI symptoms. Next, 632 cat sera were tested from five different 
countries. As a result, we could show a strong correlation between cat adenovirus and cat 
immunodeficiency virus (FIV) infections. Because in all these experiments we used ELISA, 
in the next study we have optimalised the ELISA procedure using the Taguchi optimalisation 
method. This sophisticated method can test the effect of different conditions by reducing 
the interactions between the variables, providing result in one step. Finally, in the last study 
the adenovirus viropexis was investigated. We could show that the epsilon-coatamer protein 
plays a crucial role in the endosomal transport, hence enhancing the virus leaving the early 
endosomes. In this experiment, we used Ad5-Luc3 virus and CAR-transfected CHO cells.
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V. 4.
HHV-6 and inhibitory KIR2DL2 NK cell receptor 
Dario Di Luca 
Department of Medical Sciences, University of Ferrara, Italy 
Human Herpesvirus 6 (HHV-6) is frequently present in the human population. Infection takes 
place during the infancy, and thereafter the virus persists in latent form. HHV-6 is mainly 
lymphotropic, but it can infect also other cell types. Two viral variants have been described. 
In spite of their similarity, HHV-6A and HHV-6B differ for biological, pathological, func-
tional characteristics and are considered as different viral species. Primary infection by HHV-
6B causes Exanthema Subitum, while so far HHV-6A pathogenesis during primary infection 
still has to be elucidated. Nevertheless, both viruses can reactivate and cause severe diseases, 
mainly (but not exclusively) in immunocompromised patients. Recently we described as-
sociation of HHV-6A with autoimmune thyroiditis (Hashimoto’s) and female primary idio-
pathic infertility. 
Natural killer (NK) cells, as part of the innate immune system, play a key role in host 
defense against viral infections. Recent advances have indicated that NK cell activation and 
function are regulated by the interplay between inhibitory and activating signals. To investi-
gate the possible effect of HHV-6A and HHV-6B infection, as well as of other human herpes-
viruses, on NK cell response, we will present two models of study: i) infection in Multiple 
sclerosis patients; ii) infection at the NK/endometrium interface. 
We have recently shown that NK cells from a subgroup of Multiple Sclerosis (MS) pa-
tients have an impaired response to Human Herpesvirus infection (Rizzo et al. J Neuroim-
munol. 2016) and are characterized by the expression of KIR (Killer Ig-like receptors) 2DL2 
inhibitory receptor. NK cells were engineered to switch on and off KIR2DL2 expression by 
demethylation and transfection. The turning on of KIR2DL2 resulted in NK cell inability to 
control HHV-6A and 6B infection (but also of other human herpesviruses, such as HSV-1 and 
EBV), with a 3 log increase in viral production. The KIR2DL2 switch off re-established NK 
cell activation towards herpes-infected cells, to levels detected in parental cells. These results 
show the potential role of KIR2DL2 in determining susceptibility to herpesviral infection. 
We have recently shown the presence of HHV-6A DNA in 43% of endometrial biop-
sies from primary idiopathic infertile women, but not in fertile women (Marci R et al. 
PlosOne 2016). The presence of HHV-6A infection seems to affect endometrial specific CD-
56brightCD16 − NK cells percentage and activation, with infertile HHV-6A positive women 
with a decrease in specific endometrial resident NK cells, a different expression of activating 
and inhibitory receptors and a hampered DNA sensor STING-STAT6 signalling. 
For the first time, we show the mechanisms responsible for NK cell activation and func-
tion in the control of HHV-6 infection. These data will help the development of antiviral and 
NK cell-based therapies.
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V. 5.
In vitro studies on the immunomodulatory aspects of HHV-6,  
HHV-7-associated encephalitis 
Joseph Ongrádi, Balázs Stercz, Valéria Kövesdi and Katalin R. Tarcsai 
Institute of Medical Microbiology, Semmelweis University, Budapest, Hungary 
Roseoloviruses, as human herpesvirus (HHV)-6A, 6B and HHV-7 infect almost all small 
children worldwide consequently establish lifelong latency in CD4+ immune cells and neu-
ronal cells. Depending on genetic background, geographical regions, immune status or other 
underlying diseases at any age, these viruses alone or in coinfections with other pathogens 
can induce different immunological and neurological disorders. Upon primary infection, all 
three species might elicit sporadic form of encephalitis. HHV-6A can be associated with 
rhomboencephalitis, HHV-6B with or without exanthema subitum. Delayed HHV-7 infection 
might induce severe encephalitis with generalized symptoms and lifelong sequelae. The most 
severe forms of encephalitis develop in immunocompromised patients due to underlying 
malignancies and immunosuppressive and cytotoxic drug therapy. Encephalitis associated 
with generalized HHV-6B and CMV reactivation is usually part of generalized symptoms 
after liver transplantation. Frequently lethal forms of encephalitis arise after bone marrow 
or haematological stem cell transplantation. Additional risk factors are young age and pres-
ence of chromosomally integrated HHV-6A and/or HHV-6B in either donor or recipient, un-
matched cord blood cell transplantation and repeated hematopoietic stem cell transplantation. 
HHV-6 damages the brain stem, hippocampus, limbic tissue. The most severe manifestation 
is post-transplantation acute limbic encephalitis with extreme high mortality. Beside direct 
brain cell damages exerted by Roseoloviruses, alterations in the intrathecal cytokine pattern 
significantly contribute to the disease course. Rapid microbial differential diagnosis, and dur-
ing disease course and treatment, continuous monitoring of the viral load and cytokines pri-
marily in the cerebrospinal fluid are required. No FDA approved treatment regimen is avail-
able. Ganciclovir, valganciclovir, foscarnet or cidofovir therapy or pre-emptive approach 
have been shown a variable value. Restricted use of immunosuppressive and cytotoxic drugs, 
avoiding other drugs with known Roseolovirus activating potential would be desirable in an 
individual basis.
V. 6.
New challenges in CMV infections 
Davide Abate 
University of Padova, Padova, Italy 
Human Cytomegalovirus (CMV) represents a prominent cause of fetal infection, causing 
sensorineural abnormalities, hearing impairment and developmental disorders. At the pres-
ent several diagnostic methods are available to assess congenital infection during pregnancy, 
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however a variable fraction (30-2%) of CMV infected pregnant women transmit the virus to 
the fetus, depending from maternal serostatus at conception. The cell-mediated immune re-
sponse has been investigated as potential factor involved in the congenital infection. Surpris-
ingly, high levels of maternal T-cell mediated immune response were found to be associated 
with congenital CMV transmission, especially in presence of maternal low IgG avidity level. 
Thus, congenital CMV infection may be due to an imbalanced Th1/Th2 response in pregnant 
women.
V. 7.
The 35 years of HIV/AIDS – What next?
Erwin Tschachler
Medical University of Vienna, Austria 
It has been 35 years ago that in 1982 the CDC formulated the surveillance definition for 
the newly occurring acquired immunodeficiency syndrome (AIDS). What followed was a 
complex success story of biomedical research: already in 1983 was HIV-1 (then HTLV-II/
LAV), the infectious agent which causes this disease, discovered and 2 years later tests to 
detect HIV-1 infections were widely available.  Intensive basic research rapidly identified 
potential drug targets and the first drugs to combat HIV entered clinical trials already in 
1986. Ten years later, a highly efficient combination anti-retroviral therapy, which broke the 
vicious cycle of viral propagation and loss of immune cells, was introduced. These drugs 
target different steps of the viral life cycle and have transformed HIV-disease from a rapidly 
progressing fatal illness into a chronic condition. In fact, today both the life expectancy and 
the quality of life of HIV-infected patients taking antiretroviral therapy is approaching the 
one of non-infected individuals. The nowadays wide availability of antiretroviral drugs and 
the introduction of drugs as post exposure prophylaxis have helped to lessen also the spread 
of the virus. On the downside, despite continuing efforts, the search for effective HIV-1 
vaccines have so far not (yet) yielded satisfying results. As to the elimination the virus from 
infected individuals the fact that HIV-1 target cells that carry mutations in one of its receptors 
are resistant to infection, strongly hint that the introduction of this receptor variant into he-
mopoeitic stem cells through genetic engineering might represent a way forward to achieve 
a cure from HIV-1 infection in the future.   
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V. 8.
Contribution of advanced molecular virology to the HIV surveillance in 
Hungary 
Károly Nagy 
Institute of Medical Microbiology, Semmelweis University, Budapest, Hungary 
In the second decade of the 21st century Hungary is still in a good epidemiological situation 
concerning HIV infections and AIDS. It is the result of the strict but consistent introduction 
of nationwide HIV screening in 1985, the good cooperation of clinicians, researchers and 
government officials, and the early advanced molecular virological research. This latter had 
been implemented by the author resulting in the first isolation of HIV in Hungary in 1988, 
virological confirmation of the first AIDS case in the country, and the determination of HIV-1 
B subtypes as the major circulating HIV variants in Hungary. 
HIV screening in risk groups had been introduced in 1985, when the first infections were 
confirmed. During the last 32 years altogether 3344 HIV infection ( 3/100.000) had been 
reported and the cumulative number of AIDS cases are 892. Distribution of HIV subtypes 
and genetic resistance (allele frequencies of CCR5-Δ32, CCR2-64I and SDF1-3’A ) were 
determined by molecular virological methods, antiretroviral drug resistance in primary HIV 
infection and transmission of circulated recombinant forms of HIV (CRF) in migrants were 
analysed by genotyping (Truegene HIV-1 Genotyping System /Siemens/). New approach in 
inhibiting HIV infection by modifying SH-groups of CD4 and HIV gp120 env using novel 
thyolated nucleosides was implemented for which HIV viral pseudotypes were developed. 
In the last 32 years MSM is still the highest risk group, while HIV infection is low among 
i.v. drug users. Genetic resistance to HIV representing CCR5-Δ32 was found in 12% of 
general population and 15% in ethnic gypsy minority. Genotyping revealed, that approx. 
15% of primary HIV infections are transmitted by drug resistant mutants mainly in MSMs. 
After 2004, when Hungary joined to the European Union migration increased mainly from 
SE Asia and Africa, resulting in the appearance of new HIV subtypes and African CRF, such 
as CRF02_AG (28.5%), CRF06_cpx (17.8%) and CRF11_cpx(3.6%). New pathway of HIV 
entry mechanism has been revealed, and experimental novel entry inhibitor DS53 developed 
locally acting on cell surface SH-groups concentrated by cell membrane lipid rafts was ef-
fective in vitro in 0.75 uM. 
Transmission of drug-resistant HIV during primary infection, penetration of African CRFs 
raise serious clinical and public health consequences. To maintain the recent favourable epi-
demiological situation screening programs are to be continued, rapid HIV tests had been in-
troduced, HIV genotyping at the time of diagnosis should be the standard of care, prevention 
policies including PrEP and introduction of novel compounds, among them entry inhibitors 
in the treatment are necessary.
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V. 9.
Vector-borne diseases threatening Europe: dengue, chikungunya, zika 
Anna-Bella Failloux 
Institut Pasteur, Department of Virology, Arboviruses and Insect Vectors, Paris, France
Some mosquito species have expanded their geographic distribution as a consequence of hu-
man activities, both in creating conditions favourable for their proliferation, and introducing 
means to passively transport them across borders. The Asian tiger mosquito Aedes albopictus 
is emblematic of how passive transport has contributed to both vector invasion, and the sub-
sequent emergence of arboviruses in these regions. First detected in 1979, Ae. albopictus is 
now present in at least 20 European countries and has been incriminated as the main vector 
of dengue (DENV) and chikungunya (CHIKV) viruses. While eradicated from Europe after 
World War II, autochthonous cases of dengue have been reported again in Europe since 2010: 
in France in 2010 and 2014, Croatia in 2010 and Madeira in 2012. After a first outbreak of 
chikungunya in Italy in 2007, local transmission was confirmed repeatedly in Europe and 
mainly associated to a CHIKV belonging to the East-Central-South-African genotype. How-
ever, the role of Ae. albopictus in the transmission of Zika virus (ZIKV) is still unclear as 
no human cases were reported in Europe despite hundreds of imported cases returning from 
Zika-epidemic regions of South America and the Caribbean. Nevertheless, as most arbovi-
ruses, ZIKV can evolve and become better adapted for a transmission by Ae. albopictus like 
what happened with CHIKV. Based on our vector competence studies, we will discuss on the 
recent emergence of arboviral diseases in temperate regions.
V. 10.
The Ebola outbreak – is it over? 
Bernadett Pályi1, Nóra Magyar1 and Zoltán Kis1,2 
1National Biosafety Laboratory, National Public Health Institute, Hungary
2Institute of Medical Microbiology, Semmelweis University, Hungary
Ebola virus was discovered in 1976, but until the West-African outbreak in 2013−2016 only 
sporadic cases were reported and scattered across Africa attributed to the Ebola virus, with 
maximum a few hundred cases. Ebola Virus Disease (EVD) is a zoonotic disease, and the 
reservoirs of the virus are different bat species. The deforestation and the growing number 
of human population increase the likelihood for humans to come into contact with the dis-
ease reservoirs facilitating a possible outbreak. The ease of traveling and movement across 
borders can contribute to the spread of the disease to surrounding countries. Moreover, the 
poor public health system, shortage of health workforce, financial problems are all important 
challenges in controlling future Ebola outbreaks in African countries. The virus can per-
sist for a long time especially in male reproductive tract that may enable virus transmission 
from recovered and non-symptomatic EVD survivors. This new finding is implicating the 
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initiation of an entirely new way of EBOV transmission. Experimental recombinant Ebola 
vaccines will be important in the future outbreaks and one dose can generate quick immune 
response, however it has not been tested in real outbreak situation and it is not clear how long 
such immunity lasts.
V. 11.
Laboratory diagnosis of Zika virus
Orsolya Nagy
National Public Health Institute, Hungary
The Zika-virus, an arthropod-borne flavivirus, has become a significant public health con-
cern in the last ten years due to its rapid spread to new geographical areas, and association 
with severe neurological symptoms and intrauterine malformations. Not only its overlapping 
endemic regions, shared clinical symptoms and common distributing vectors with Chikungu-
nya virus and Dengue virusmake its diagnosis challenging, but the characteristic serological 
cross reactivity of the Flavivirus genus also complicates the evaluation. In Hungary, West-
Nile virus and tick-borne encephalitis virus, two important members of the Flavivirus genus 
are widespread. Part of the population is vaccinated against tick-borne encephalitis. More-
over, travellers to tropical and subtropical regions are at risk of getting infected with other 
flaviviruses such as Dengue or yellow fever virus. Besides describing the complexity of the 
serological diagnostics of Zika virus, the presentation is aimed at giving an overview of the 
molecular methods regarding the time of virus shedding in various sample materials. Some 
interesting case reports will also be highlighted, to give a better understanding of diagnosing 
Zikavirus infection as a secondary flavivirus infection.
V. 12.
Hepatitis B and C genotypes in Hungary 
Mária Takács and Ágnes Dencs 
National Public Health Institute, Division of Virology, Hungary
 
Molecular analysis of viral genomes for genotyping is routinely used in the diagnosis of 
hepatitis B and hepatitis C virus infections. Genotypes are genetic variants of a virus species 
characterized by the difference in the nucleic acid sequence of their genomes. Genotypes 
show a specific geographical distribution and they may also differ in their virological fea-
tures, clinical outcome of the infection and response to antiviral therapy. To date, 10 hepatitis 
B virus (HBV) genotypes have been described. They show more than 8% genetic divergence 
and are further classified into sub-genotypes differing by 4−8% of the genome. In Hungary 
HBV genotypes A and D are the most common, but occasionally genotypes B, C and G have 
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also been detected. Infection with genotypes A and D result in chronicity at a higher rate 
than B and C. Genotype D shows the worst response to interferon therapy. Hepatitis C virus 
(HCV) strains are classified into 7 genotypes and a large number of subtypes. About 90% of 
Hungarian HCV carriers are infected with genotype 1 viruses, and the majority of them are 
subtype 1b. Genotype 3 is more common in intravenous drug users than the general popula-
tion. Genotypes 2 and 4 also occur, but are rare. Genotype 1 and especially subtype 1b has 
been the most difficult to treat using interferon-based therapy, but with the latest interferon-
free regimens sustained viral response is over 90%.
V. 13.
The experience with the treatment of Hepatitis C infection
László Rókusz
Department of Medicine, Military Hospital HDF, Budapest, Hungary
Approximately 0.7% of the population of Hungary (70,000 patients) can be infected with 
hepatitis C virus (HCV). The majority of them is unaware of their condition.
The pegylated interferon + ribavirin dual treatment that has been used between 2003 and 
2012 on patients infected with HCV genotype 1 (G1) could have cured 40-45% of naïve pa-
tients, and 5-21% of patients who received prior, failed treatments.
Addition of I. generation DAA (direct acting antivirals) – protease inhibitors (BOC/TVR) 
to dual therapy with PEG IFN-alfa with RBV, yielded SVR rates 63-75%; 59-66% respec-
tively.
From 2014, other direct acting antivirals are registered for the treatment of chronic hepa-
titis C in different combinations, including short duration (8-12 weeks) interferon-free regi-
mens, with a potential efficacy over 90%.
Due to budget limitations therapy is covered only for a proportion of pts by the Hungarian 
National Health Insurance Fund. Approved treatments are restricted to the most cost-effec-
tive combinations based on the cost/SVR value in different patient categories with recom-
mendation of the Hungarian Hepatitis Therapeutic Committee.
We have a nationwide uniform database, Hepatitis Registry (HepReg). In the HepReg are 
about 1200 pts on the waiting list. 
All treatments that are covered from a pre-defined budget by the National Health Insur-
ance Fund are to be centrally approved. These treatments are restricted to the most cost-ef-
fective combinations based on the cost per sustained viral response value in different patient 
categories with consensus between professional organizations, Insurance Agency and patient 
organizations. 
In Hungary GT 1 is the most frequent HCV GT (about 95%), and the incidence of HCV, 
subtype 1b is dominant. 
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We have collected data from Hungarian Hepatitis Registry since 2013, who suffered 
chronic hepatitis C GT 1b. The patients with fibrosis stadium were more than 75% − F4 (by 
fibroscan screening).   
We achieved the good SVR results from IFN based therapy, because these patients have 
F1 fibrosis stadium, mostly IVDU patients from prison.  The efficacy of triple therapy (PEG 
IFN + RBV + Boceprevir or Telaprevir) was not superior, than IFN-based therapy.  
The IFN-free therapy was introduced in Hungary in the year 2015. The efficacy was ex-
cellent (> 96% SVR), taken into account that fibrosis stadium treated patients were mostly 
F4-F3. 
Cirrhotic pts who achieve an SVR should remain under surveillance for HCC every 6 
months by ultrasound (like pts with advanced fibrosis, METAVIR score F3), and for oesopha-
geal varices by endoscopy if varices were present at pre-treatment endoscopy.
The presence of cofactors for liver diseases, such as history of alcohol drinking, obesity 
and/or type 2 DM, may determine that additional assessment are necessary.
Long-term post-SVR follow-up studies showed that, the risk of developing HCC remains 
in pts with cirrhosis who eliminated HCV.
Screening for HCV infection is presently based on the detection of anti-HCV antibodies.
If anti-HCV antibodies are detected, HCV RNA should be determined to identify pts with 
on-going infection, and make a decision to treat this patient and achieve a SVR.
V. 14.
The evolution of molecular diagnostic in HPV
Csaba Jeney
Institute of Medical Microbiology, Semmelweis University, Budapest, Hungary
Cervical cancer preventive screening as in the past as it is today one of the most successful 
areas of diagnostic, medical developments. From early cytology concepts to the improved, 
standardized, present-day form of the cytology and more recently HPV testing and modern 
triage markers, we can withstand the continuous improvement of the cervical cancer man-
aging tools. At present these technologies not only co-exist but augment each other. This 
process of technological accretion has involved the widespread adoption of novel automated 
technologies: liquid-based cytology (LBC), robotized HPV detection platforms and automat-
ed slide readers. This presentation explores the consequences of this development for today 
diagnostic and clinical managment and provides insight into future developments.
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Section II. 
The challenges of the multidrug resistant 
bacteria and new therapeutic approaches 
B. 15.
Global trends in the antimicrobial resistance
Christian Giske
Karolinska Institute, Stockholm, Sweden
In recent years resistance levels in important Gram-positive pathogens such as Staphylococ-
cus aureus, Streptococcus pneumoniae, and Enterococcus species have only increased to 
a modest degree and in some cases even decreased. This has been paralleled by develop-
ment of several novel drugs targeting gram positive pathogens. In gram-negative pathogens a 
steady increase in resistance levels has been observed over the last decade, resulting in a very 
concerning situation with regards to cephalosporin resistance in Escherichia coli and both-
cephalosporin and carbapenem resistance in Klebsiella pneumoniae. Moreover, the last years 
an increase in colistin resistance has also been observed, particularly among carbapenem-
resistant K. pneumoniae. The Acinetobacterbaumannii-group is increasingly often observed 
in blood cultures and a high proportion of the isolates are resistant to carbapenems. During 
the same time resistance in Pseudomonas aeruginosa has not increased to the same degree 
as for other Gram-negative pathogens. The presentation discusses overall trends and relation 
to clonal expansion of some epidemic clones carrying important resistance determinants, as 
well as the importance of asymptomatic carriage as a source for the emergence of resistant 
strains in severe infections. Finally, emerging resistance to recently introduced antimicrobial 
agents is also discussed.
B. 16.
Multidrug resistant Gram-negative pathogens in Hungary 
Béla Kocsis 
Institute of Medical Microbiology, Semmelweis University, Budapest, Hungary 
Multidrug resistant (MDR) Gram-negative pathogens are an ongoing challenge in Hungary. 
During the decades the ease as these pathogens have disseminated in the country and con-
tributed to the increased number of infections is remarkable. The first reports regarding MDR 
Gram-negatives in Hungary date back to 1998 and 1999 when the first SHV-2 and SHV-5 
extended-spectrum beta-lactamase (ESBL)-producing clinical isolates of Enterobacteriaceae 
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appeared. In 2005 widespread dissemination of CTX-M-15 type ESBL-producing Klebsiella 
pneumoniae was related to high-risk clones namely, ST11, ST15 and ST147. These clones 
developed resistance against fluoroquinolones, aminoglycosides and sulfonamid. 
Emergence of carbapenem resistance among Pseudomonas aeruginosa and other Gram-
negatives represents alert in numerous hospital wards in Hungary. First reports of VIM-4 
producing P. aeruginosa were published in 2004 and later on it was detected all over the 
country. Aeromonas hydrophila, Klebisella spp. and Enterobacter cloacae carrying integron-
borne blaVIM-4 were also detected in Budapest. Hence, reports of NDM, OXA-48-like and 
KPC in our country still VIM is the dominant carbapenemase. 
Recently, appearance of acquired colistin resistance has been observed. An outbreak of 
KPC-2 producing K. pneumoniae ST258 in North-east Hungary was the first detection of 
acquired colistin resistance, however sporadic cases of colistin resistant Escherichia coli, 
Enterobacter asburiae, Pseudomonas spp., and Acinetobacter baumanii have been reported 
to date.
B. 17.
Multi-drug resistant Gram-positive bacteria in Hungary
Ákos Tóth
Department of Bacteriology, National Public Health Institute, Hungary
Infections caused by multidrug-resistant Gram-positive bacteria represent a major public 
health burden, not just in terms of morbidity and mortality, but also in terms of increased 
cost on patient management and implementation of infection control measures. Among these 
Staphylococcus aureus and Enterococcus spp. are established pathogens in the hospital en-
vironment, and their frequent multidrug resistance complicates or even makes the therapy 
impossible. 
Although, European mean percentage for methicillin resistance in S. aureus (MRSA) de-
creased significantly between 2013 and 2016 (from 18.1% to 13.7%) based on the EARS-Net 
data, in Hungary the rate of methicillin resistance among invasive S. aureus isolates increased 
(25.6% in 2016) with alternating favourable and unfavourable changes in the last 10 years. 
In this period the population structure significantly changed among epidemic MRSA strains. 
While New York/Japan (ST5-MRSA-II) and Southern German (ST228-MRSA-I) clones 
were predominant in the early 2000s these were replaced by EMRSA-15 (ST22-MRSA-IV) 
by end of the 2000s but the proportion of ST5-MRSA-II increased again in the last 5 years. 
The relevance of MRSA outside of hospitals (CA-MRSA, LA-MRSA) has also increased in 
the last 10 years, moreover the first case of mecC-positive MRSA has been described in 2016. 
The European mean percentage for vancomycin resistance in Enterococcus faecium was 
11.8% in 2016 and the trend did not change significantly during the period 2012−2016. 
In Hungary the vancomycin resistance was below the European mean in 2012 (7.1% vs 
9.0%) but was double in 2016 (22.4% vs 11.8%). The molecular epidemiological results 
suggest that countrywide spread of hospital adapted, vanA-positive E. faecium lineages (e.g. 
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BAPS2.1a and BAPS3.3a − formerly called CC17) harbouring pRUM-like plasmids with 
unique Tn1546::IS1251 transposon variant could have caused the sharp increase in van-
comycin resistance after 2012. Furthermore, since 2015 a vanA-positive E. faecalis CC28 
strain showing low level β-lactam resistance and harbouring unusual vanA-coding- plasmid 
disseminates in Hungary. Thus, efforts to optimize the use of antimicrobials against Gram-
positive bacteria and to recognize emerging mechanisms of resistance have to be one of the 
major public health and clinical priorities.
B. 18.
Global trends in the seroprevalence in Streptococus pneumoniae
Mark van der Linden
Referenzzentrum für Streptokokken, Abteilung Medizinische Mikrobiologie, Universitätsklinikum, 
Germany
Streptococcus pneumoniae remains a major cause of infectious disease, especially among the 
very young (children <5 years of age) and the elderly (>60 years of age). Apart from causing 
diseases like otitis media, pneumonia and meningitis, pneumococci colonize the nasophar-
ynx, with the highest level of carriage reported from pre-school age children. 
Pneumococcal conjugate vaccines (PCVs) have been developed to reduce the burden of 
disease among children and, through mucosal immunity, also reduce the carriage of serotypes 
included in the vaccine. So far, three different PCVs have been used for the vaccination of 
children in many countries worldwide: PCV7, containing antigens for 7 pneumococcal sero-
types, PCV10 (10 serotypes) and PCV13 (13 serotypes). 
In countries that vaccinated children under the age of two years this has had a profound 
effect on the incidence of pneumococcal disease both among vaccinated children as well as 
among non-vaccinated children and adults (herd protection). Incidence of vaccine serotypes 
have been strongly reduced, but non-vaccine serotypes have increased in prevalence (re-
placement). In most countries incidence of invasive pneumococcal disease among children 
has reduced. Among adults, herd protection has changed the serotype distribution, with vac-
cine serotypes disappearing, but the overall burden of disease seems mostly unaffected.
B. 19.
Pneumococci carried by healthy children in Hungary, 2009−2015 
Orsolya Dobay 
Institute of Medical Microbiology, Semmelweis University, Hungary
Streptococcus pneumoniae is one of the leading human pathogens, and it is still the cause of 
death of half million children <5 years old worldwide. The infection often derives from symp-
tomless carriers, usually from small children. To prevent pneumococcal infections, polysac-
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charide and conjugate vaccines (PCVs) were developed, both based on the most important 
antigen of the bacterium: the polysaccharide capsule. Although these vaccines contain only a 
limited number of serotypes out of the total of 94 (PCV 7, 10 or 13), they were proven to be 
remarkably successful in decreasing pneumococcal infections, and also influenced carriage. 
On the other hand, pneumococci responded rapidly to the vaccine pressure and a large scale 
serotype arrangement was observed all over the world. 
Vaccination with PCV-7 basically started in 2009 in Hungary, and PCV-13 became an 
obligatory vaccine in 2014. We have followed the serotype changes among the carried pneu-
mococci between 2009 and 2015. While in the first few years the old serotypes dominated, 
later these mostly vanished, and previously rare types emerged. Especially the multi-resistant 
serotype 19A (which is present only in PCV-13) emerged worryingly, but later it was also 
suppressed successfully. Due to the dynamic changes in serotypes, pneumococci should be 
monitored continuously and new vaccines should be developed.
B. 20.
Antibiotic therapy in the age of multiresistant bugs − a clinician’s 
approach 
Endre Ludwig 
Joined Saint Stephan and Saint Ladislaus Hospital–Clinic, Budapest, Hungary
The rapid spread of the multiresistant bacteria poses a difficult challenge for the medical 
community in the treatment of severe infections. Though several new antibiotics will be 
launched in the near future, their availability will not solve the problem of bacterial resis-
tance. The basic principles of the treatment of severe infections are well established: adequate 
antibiotic treatment (combination) should be introduced within 3 hours from the recognition 
of the infections. The use of antibiotic combinations in empiric therapy in cases presumably 
due to multiresistant bugs is clearly indicated together with deescalation strategy. However, 
the superior clinical efficacy of combinations in targeted therapy is controversial in infec-
tions caused by carbapenemase producer Enterobacteriacea, Pseudomonas aeruginosa and 
Acinetobacter baumannii, despite of the plethora of positive in vitro results. It seems, that 
the use of antibiotics according to their pharmacodynamic characteristics may improve their 
clinical efficacy. The introduction of individualized therapy based on the regular monitoring 
of antibiotic serum concentrations might be an important step forward.
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B. 21.
Dissimilar fitness associated with resistance to fluoroquinolones 
influences clonal dynamics of various multiresistant bacteria 
Miklós Füzi 
Institute of Medical Microbiology, Semmelweis University, Hungary
Authors’ group previously demonstrated that diverse fitness cost associated with resistance 
to fluoroquinolones has substantially contributed to the dissemination of the major inter-
national clones of methicillin-resistant Staphylococcus aureus (MRSA) and multiresistant 
Klebsiella pneumoniae. Since the major clone isolates are multiresistant their spread resulted 
in elevations also in the rates for non-fluoroquinolone antibiotics (like β-lactams, aminogly-
cosides, macrolides). The findings were subsequently confirmed by other laboratories who 
also showed that a similar mechanism was responsible for the dissemination of the major 
clones of two additional pathogens (multiresistant E. coli and Clostridium difficile). Authors 
review the related literature and demonstrate that a more judicious use of fluoroquinolone 
type antibiotics should result in an amelioration of the general antibiotic resistance situation.
B. 22.
FDA Pathways to Antibiotic Approval
Carl N. Kraus
Raleigh-Durham, Arrevus Inst., USA
The process of transforming a molecule to a medical therapeutic in order to secure United 
States marketing authorization is well-established, but can often seem confusing.  This confu-
sion can be even more pronounced with antibiotic regulatory submissions, due to the growing 
number of options available to drug sponsors from the US FDA.  The emergence of these 
options is due in part to heightened fear over antibiotic resistance and the mounting worry 
that novel treatments will be unavailable to patients suffering from resistant infections. Such 
concerns have resulted in new legislation, such as the FDA Safety and Innovation Act (FDA-
SIA) and the 21st Century Cures Act (Cures Act). In this session, we will discuss the history of 
the FDA’s drug-review process, the various pathways available to secure antibiotic approval, 
and a handful of recent approvals to illustrate some of these more creative routes to approval.
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B. 23.
Mechanistic studies on short proline-rich antimicrobial peptides 
Ralf Hoffmann
Center for Biotechnology and Biomedicine, Universität Leipzig, Germany
Proline-rich antimicrobial peptides (PrAMPs) are a large diverse family expressed in many 
insects (~20 residues) and mammals (~60 residues) except humans. Thus, they represent 
interesting lead structures for further pharmaceutical developments to support the human 
innate immune system. Indeed, several research groups have proven the high efficacies 
of optimized PrAMPs in different murine infection models. Their bactericidal mechanism 
was partially elucidated by identifying chaperone DnaK as binding partner and transporter 
SbmA as part of the bacterial uptake system. We could show that slight structural changes 
of PrAMPs allow them to use an additional transporter system reducing the risk of bacte-
rial resistances, which simultaneously increased also the antibacterial activity. The uptake of 
short PrAMPs appears to be irreversible and most PrAMPs are either not degraded by cel-
lular enzymes or the degradation products bind the target as well as the full-length peptide. 
In the cells, PrAMPs target chaperone DnaK disturbing most likely proper protein folding or 
the ribosome. We could map the binding site of oncocin to the peptide exit tunnel of the 70S 
ribosome with dissociation constants in the low nanomolar range, which was confirmed for 
further PrAMPs afterwards. The large binding site of oncocin overlaps with the binding sites 
of different small molecule antibiotics. Expectedly, these PrAMPs inhibit protein translation 
efficiently in vitro and in vivo. Remarkably, apidaecin and a few other PrAMPs bind equally 
well to the ribosome without inhibiting protein translation in vitro. In vivo, apidaecin-type 
PrAMPs disturb the assembly of the large 50S subunit of the bacterial 70S ribosome forming 
dead-end intermediates that cannot assemble to functional ribosomes. Inhibition of protein 
translation is a lethal effect that bacteria cannot escape, which explains also their long lasting 
post-antibiotic effect.
B. 24.
Are the peptid antibiotics the future?
László Ötvös
Temple University, Philadelphia, USA
Compared to small molecule drugs, peptide therapeutics to human targets offer increased 
specificity and selectivity and lower toxicity. For better or worse, the in vivo efficacy of 
antimicrobial peptides include a number of bacterial targets and host defense mechanisms. 
On one hand, this multimodal activity allows biological actions in a wider playing field and 
lower risk of resistance induction. On the other, the in vitro individual activity contributions 
may not be enough to justify drug development in a regulatory setting when measured rela-
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tive to benchmark figures. Having said this, the specific biodistribution pattern and preferred 
sites of action of peptides may allow monotherapy in specific cases such as skin conditions or 
complicated urinary tract infections. When used in combination with legacy antimicrobials, 
antimicrobial peptides may specifically target resistance mechanisms or proteinaceous toxin 
production in very low doses, giving second lives to existing small molecule antimicrobials 
and host defense peptide therapies alike.
B. 25.
Experiences with A3-APO antibacterial peptide 
Eszter Ostorházi
Institute of Medical Microbiology, Semmelweis University, Hungary
Antimicrobial peptides (AMPs) were first thought to fight microorganisms by disintegrating 
bacterial membranes and later by inhibiting bacteria-specific intracellular processes. How-
ever, ever increasing evidences indicate that AMPs accumulate around and modulate the 
immune system both systemically and in cutaneous and mucosal surfaces where injuries and 
infections occur. 
The proline-arginine-rich antibacterial peptide dimer A3-APO was designed based on a 
statistical analysis of peptide and protein sequences derived from natural insect products. 
The in vitro activities of A3-APO are due to multiple biochemical effects, including bacte-
rial membrane disruption, inactivating DnaK, the 70-kDa bacterial heat shock protein. DnaK 
deactivation was shown to inhibit proper folding of bacterial proteins, including resistance 
enzymes and proteinaceous toxins. Our in vitro experiences confirmed that A3-APO inhibits 
growing of bacteria including moreover multidrug resistant strains at low concentrations. It 
also inhibits in vitro bacterial toxin production, and in combination recovers the efficiency of 
small molecular antibiotics against resistant strains. 
A3-APO was exceptionally active in a series of systemic and local animal models of 
bacterial infection. ESBL producing Escherichia coli, multiresistant Acinetobacter bauman-
nii, KPC producing Klebsiella pneumoniae, Methicillin resistant Staphylococcus aureus, and 
anaerobe Propionibacter acnes were used as infective agents. The readout of efficacy was 
improvement of survival and reduction of blood or tissue bacterial load. The peptide was ac-
tive in vivo even if it completely failed to kill the pathogenic strains in vitro. Multiple lines 
of evidence suggested that A3-APO fights infections, at least partially, by preventing inflam-
mation at the site of infection.
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Section III.  
The importance of the human microbiome
M. 26.
The bioinformatical analysis of the microbiome
Sean Kennedy
Institut Pasteur, Paris, France
The human intestinal microbiome contains over 100 trillion cells, thousands of species and 
a commensurate huge diversity of genes and functions. This environment, coupled to the 
enormous data generated by modern NGS sequencing, represents unique challenges when 
it comes to analysis. The Biomics Unit at the Institut Pasteur has developed at toolbox of 
pipelines to address this problem. SHAMAN (http://shaman.c3bi.pasteur.fr/) is a SHiny ap-
plication for Metagenomic ANalysis including the normalization and the differential analy-
sis based on the best current statistical models of metagenomic data. SHAMAN is coupled 
MASQUE which handles 16S/18S/ITS sequence analysis and to and multiple visualization 
and MBMA which is used for identification of reads from shotgun metagenomics. A further 
tool was recently developed which permits the reconstruct of the genome of microorganisms 
from shotgun metagenomic data. This tool is especially important in strain identification and 
functional prediction along with the statistical analysis in clinical studies. Here we present 
the current state-of-the-art techniques for metagenomic studies. Examples and pitfalls in the 
sequencing and analysis of metagenomic data will be presented.
M. 27.
The effect of the antibiotics on the microbiome
Dóra Szabó
Institute of Medical Microbiology, Semmelweis University, Hungary
The discovery and use of antibiotics have changed modern medicine. However, the exces-
sive consumption of antibiotics creates many threats, because antibiotic therapy can affect 
not only the target pathogen but also the commensal flora of human host. The antimicrobial 
treatment is known to cause short-term changes in the composition of the normal human mi-
crobiota, but also long-term consequences have been shown. The effect of antibiotic-induced 
microbiota alteration increases the susceptibility to intestinal infections, which can stem from 
newly acquired pathogens or from the sudden overgrowth and pathogenic behavior of op-
portunistic organisms already present in the microbiota. In particular, antibiotic associated 
diarrheas due to Clostridium difficile are frequent occurrence. 
The use of antibiotics selects antibiotic resistant strains of bacteria, but not only in those 
which the antibiotic is directed towards but also among the normal microbiota. The dysbiosis 
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brought about by antibiotics bear the added disadvantage of enriching the microbiota in resis-
tant organisms. The human gut microbiota has been established as a significant reservoir of 
antibiotic resistance genes (ARG). ARGs are detected not just in adults, but also in children 
and in infants. Furthermore ARGs can be stably maintained in the human gut microbiome 
in the absence of direct antibiotic selection. Human gut is not just the site of accumulation 
of ARGs, but also the environment where these genes can spread among different species.
Although, the consequences of long-term persistence of antibiotic resistance in the human 
gut are currently unknown, there are high risks that this could lead to increased prevalence 
of antibiotic resistance and reduce the possibility of successful future antibiotic treatments. 
Antibiotic induced long-term alteration can also affect the basic immune homeostasis re-
lating to autoimmune diseases, the regulation of host metabolism relating to energy homeo-
stasis and adiposity.
M. 28.
Exercise and the microbiome
Zsolt Radák 
University of Physical Education, Budapest, Hungary 
The diversity of the microbiome is associated with cardiovascular fitness. The microbiome 
of individuals with higher levels of VO2max tend to produce greater amounts of butyrate, 
which is an important short-chain fatty acid to suppress inflammation. It has also been ob-
served that exercise induces a more diverse microbiome. This is an important observation 
even though exercise has not been thoroughly linked to gut integrity. Exercise normally re-
duces the risk of gastrointestinal cancer, reflux, and incidence of ulcers, fatty liver, irritable 
bowel syndrome, and diverticulitis. In addition, exercise in older animals has been demon-
strated to reduce expression of inflammatory mediators and apoptotic markers in intestinal 
lymphocytes, suggesting a protective role of exercise in intestinal health. Regular exercise 
can even reduce the progress of Alzheimer Diseases in transgenic mice, by down-regulating 
pro-inflammatory bacteria in the microbiome, like Bacteroides thetaiotamicron and Lactoba-
cillus johnsonii which level correlates well with the number and area of amyloid plaques. In 
addition, L. johnsonii produces hydrogen peroxide, therefore the suppression of this bacteria 
might be linked to the mechanism by which exercise attenuates colon cancer.
M. 29.
The role of the microbiome in the intensive care
Krisztina Madách
Department of Anaesthesiology and Intensive Therapy, Semmelweis University, Hungary
Critical illness is associated with loss of “health promoting” commensal microbes and over-
growth of pathogenic bacteria referred to as dysbiosis. Many intensive care interventions 
may further disrupt the homeostasis of the microbiome. Dysbiosis may increase susceptibil-
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ity to sepsis and organ failure, thus leading to increased morbidity and mortality. Characteriz-
ing, understanding and influencing changes in intensive care unit (ICU) patients' microbiome 
may help to improve patient care. While it is well-known that some interventions (eg. pro-, 
symbiotics, faecal microbiota transplant, selective bowel decontamination) aim to directly 
alter the composition of the microbiome, we are rarely aware of the impact of everyday 
intensive care on the holobiont. The lecture overviews the evidence based risks and benefits 
of these medical interventions with direct or indirect influence on the microbiome. Current 
evidences describing the effect of these interventions on the microbiome give an explanation 
while adhering to the guidelines of antimicrobial therapy, stress ulcer prophylaxis, clinical 
nutrition, mechanical ventilation have significant impact on the outcome. Deliberate imple-
mentation of ICU interventions with a microbiome conscious approach improves patient 
outcome. Further studies are needed to investigate the effect of medical care on the holobiont.
M. 30.
Characteristics of microbiom in paediatric- and adult patients with 
Crohn's disease 
Gábor Veres
1st Dept. of Pediatrics, Semmelweis University, Budapest, Hungary 
Inflammatory bowel disease (IBD) − including Crohn’s disease (CD) and Ulcerative colitis 
(UC) − is a complex disease in which genetic and environmental (mainly the diet) circuits es-
tablish and contribute to disease pathogenesis. Recent large-scale genome-wide association 
studies link IBD to host-microbe pathways central to sensing and signalling and mucosa-ini-
tiated effector responses. However, patterns of gut microbiome dysbiosis in paediatric- and 
adult IBD patients are inconsistent among published studies. Analysing samples from mul-
tiple gastrointestinal locations collected prior to treatment in new-onset cases, a characteristic 
pattern of microbiome in paediatric CD was established. Namely, an increased abundance in 
bacteria which include Enterobacteriaceae, Pasteurellacaea, Veillonellaceae, and Fusobac-
teriaceae, and decreased abundance in Erysipelotrichales, Bacteroidales, and Clostridiales, 
correlates strongly with disease status were described. In addition, microbiome comparison 
between CD patients with and without antibiotic exposure indicates that antibiotic use ampli-
fies the microbial dysbiosis associated with CD. Comparing the microbial patterns between 
intestinal segments indicates that at this early stage of CD assessing the mucosa-associated 
microbiome may offer unique potential for convenient and early diagnosis of CD. Based on 
the recent Paediatric CD Guideline (2014), Exclusive enteral nutrition (EEN) is a first-line 
therapy in paediatric CD thought to induce remission through changes in the gut microbi-
ome. With microbiome assessment largely focused on microbial taxonomy and diversity, it 
remains unclear to what extent EEN induces functional changes that thereby contribute to its 
therapeutic effect. Recent paper published by Dunn et al. faecal samples were collected from 
paediatric CD patients prior to and after EEN treatment. Metagenomic data were obtained 
via next-generation sequencing pathway abundance was compared between CD patients and 
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controls, and between CD patients that sustained remission and those that did not sustain re-
mission (NSR). Eight pathways differed significantly between baseline CD patients and con-
trols. In addition, examination of these eight pathways showed sustained remission patients 
had greater similarity to controls than non-sustained remission patients in all cases. Knowing 
the several differences between paediatric- and adult IBD it is not surprising that microbiom 
of those population is different. 
In summary, relative abundance of Bacteroidetes is increased and Firmicutes decreased 
in CD compared with healthy controls. Enterobacteriaceae, specifically Eschericia coli, is 
enriched. Faecalibacterium prausnitzii is found at lower abundance in CD and in those with 
postoperative recurrence.
M. 31.
Molecular signalling mechanisms underlying the stability of microbial 
communities 
Sándor Pongor, János Juhász, Balázs Ligeti and Attila Jády 
Faculty of Information Technology and Bionics, Pázmány Péter Catholic University, Hungary 
Members of multispecies bacterial communities (MBC) communicate and cooperate via 
diffusible molecules that they release into the environment, while also compete for space 
and resources. Examples of such communities include microbial mats of the oceans, the 
gut microbiota of animals and insects as well as the microbial communities of the soil. The 
best studied molecular mechanism is quorum sensing that helps bacteria to orchestrate gene 
expression programs underlying collective behaviour. In spite of the constant competition, 
MBCs can be remarkably stable over time and resilient to changes in the environment. In 
silico models suggest that common signals released into the environment may help selected 
bacterial species cluster at precise locations and that sharing of molecular signals and coop-
eration factors can stabilize this coexistence. In contrast, unilateral eavesdropping on signals 
produced by a potentially invading species may protect a community by keeping invaders 
away from limited resources. Shared bacterial signals, such as those found in quorum sensing 
systems, may thus play a key role in fine tuning competition and cooperation within multi-
bacterial communities, including the formation self-defense and regulatory equilibria that in 
turn seem essential for maintaining the stability and/or metabolic repertoire of a community. 
In particular, horizontal gene transfer seems to enhance the resilience of microbiomes against 
invading bacteria. Differential responses to related signals on the other hand seem to help 
communities to keep slower growing microbial species within the community thereby the 
metabolic repertoire will be maintained. 
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POSTER SECTION
P. 1.
Clinical and microbiological characteristics of adult invasive 
Haemophilus influenzae infections: results of a 12-year single center 
experience 
Balint Gergely Szabo1,2,3, Tamas Tirczka4 and Eszter Ostorhazi5 
1 Joined Saint Stephan and Saint Ladislaus Hospital–Clinic, Department of Infectology, Budapest, 
Hungary
2 Semmelweis University, Faculty of Medicine, Infectious Disease Specialist Training, Budapest, 
Hungary
3Semmelweis University, Doctoral School of Clinical Medicine, Budapest, Hungary
4National Center for Epidemiology, Budapest, Hungary 
5Semmelweis University, Institute of Medical Microbiology, Budapest, Hungary 
Introduction
Since the introduction of the childhood vaccine for Haemophilus influenzae serotype b, the 
burden of invasive H. influenzae disease shifted to older adults and non-vaccine preventable 
strains. However, only few observational studies were conducted among adults. Our aim was 
to describe the clinical and microbiological characteristics of adult invasive H. influenzae 
disease in a Hungarian cohort of patients. 
Methods 
We conducted a single-center retrospective case series study of adult patients treated at our 
institution between 2004 and 2016 with microbiologically proven invasive H. influenzae dis-
ease. The hospital database was used by searching ICD-10 codes consistent with H. influen-
zae disease. All consecutive cases with a compatible clinical course and ≥1 microbiological 
sample positive for H. influenzae from a sterile site were included. Hospital and available 
surveillance data from the National Center for Epidemiology concerning molecular typing 
were reviewed. Microbiological identification and antibiotic susceptibility testing was done 
at our institution. Main outcomes were clinical cure, complication rate, empirical antimicro-
bial therapy, antimicrobial susceptibility and serotype distribution. A post-discharge follow-
up was carried out by database search until last documented hospital visits. 
Results
Altogether 32 patients (median age 56.3±18.2 years; 59.3% females) were included, average 
disease incidence corresponded to 0.1 cases / 100.00 inhabitants / year. Patients mostly had 
diabetes mellitus, cardiovascular and malignant comorbidities (median Charlson score 4), a 
previously unknown illness was diagnosed in 6.3%. According to SIRS based definitions, 
56.3% of cases had severe sepsis or septic shock, 50% were accompanied by bacteraemia. 
Identified sources were mostly pneumonia and meningitis. Non-typable H. influenzae strains 
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were most prevalent (76.5%), followed by H. influenzae serotype f (11.8%). Ampicillin re-
sistance was detected in 15.4% and from these, 11.5% were also resistant to amoxicillin/
clavulanic acid. 15.4% of isolates were resistant to trimethoprim/sulfamethoxazole, 3.8% 
to macrolides. No resistance was found for 3rd generation cephalosporins, carbepenems, 
tetracyclines or quinolons. 93.8% of patients survived with ceftriaxone or levofloxacine as 
empirical therapy (78.1%), complications were detected in 34.4%. 22 patients were followed 
(median follow-up 17.0±26.8 months): 18.2% died, 13.6% had other severe infections, 
13.6% had comorbidity deterioration. 
Conclusions
In our cohort of adult patients, most invasive H. influenzae disease were caused by non-
typable and serotype f H. influenzae strains with low prevalence for ampicillin resistance. 
High clinical cure and disease complication rates were observed.
P. 2.
Clinical and microbiological characteristics and outcomes of 
community acquired sepsis: results of a single center, 1-year 
retrospective observational cohort study 
Balint Gergely Szabo1,2,3, Rebeka Kiss4, Katalin Szidonia Lenart1,2, Botond Lakatos1,  
Eszter Ostorhazi5 and Janos Szlavik1 
1 Joined Saint Stephan and Saint Ladislaus Hospital–Clinic, Department of Infectology, Budapest, 
Hungary
2 Semmelweis University, Faculty of Medicine, Infectious Disease Specialist Training, Budapest, 
Hungary
3Semmelweis University, Doctoral School of Clinical Medicine, Budapest, Hungary 
4Semmelweis University, Faculty of Medicine, Students' Scientific Association, Budapest, Hungary
5Semmelweis University, Institute of Medical Microbiology, Budapest, Hungary 
Introduction
Community acquired sepsis (CAS) is a life-threatening systemic reaction to infection start-
ing within ≤72 hours after hospital admittance. However, clinical and microbiological data 
concerning CAS, especially among Hungarian patients are sparse. 
Methods
Our aim was to retrospectively analyse the prospectively collected clinical and microbiologi-
cal data of CAS among a cohort of consecutive adult patients admitted to our 140-bed tertiary 
referral center during a 1-year study period of 2016. Patients satisfying pre-defined criteria of 
possible healthcare associations were excluded. Sepsis, severe sepsis and septic shock were 
defined according to ACCP/SCCM adult criteria. Primary outcomes were in-hospital all-
cause mortality and ICU admittance, secondary outcomes were length-of-stay (LOS) mea-
sures, rates of bacteraemia, species and antimicrobial susceptibility of causative organisms 
according to available microbiological data. 
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Results
206 patients were included in the study (mean age 58.4±20.4 years, 56.7% female), median 
Charlson score was 4. Calculated incidence of CAS was 285 / 10.000 hospital admittances 
per year. 66/206 (32.0%) cases were severe sepsis, 59/206 (28.6%) were septic shock. Fre-
quent signs of onset were fever (184/206, 89.3), two-thirds of shock cases presented with 
tachypnea (61.%, p < 0.01 vs. sepsis) and altered mental status (67.8%, p < 0.01 vs. sepsis). 
Prevalent infective sources were genitourinary (51/206, 24.8%), abdominal (51/206, 24.8%) 
and cardiopulmonary (28/206, 13.6%). Septic shock mainly arose from abdominal sources 
(39.0%, p < 0.01 vs. sepsis), whereas sepsis was caused by urinary infection (32.1%, p < 
0.01 vs. septic shock). Causative organisms were predominantly E. coli (56/216, 25.9%), S. 
aureus (14/216, 6.5%) and S. pneumoniae (15/216, 6.9%). In quarter of cases, the causative 
organism(s) could not be identified (54/216, 25.0%). Community acquired MRSA and ESBL 
producing Gram negatives as causatives were found with low prevalence (<2% of all cases). 
Bacteraemia was proven in half of cases (104/206, 50.5%). Empirical antibiotic therapy was 
mainly ceftriaxone (107/206, 52.1%), escalation was needed in some (34/206, 16.5%). In-
hospital mortality was 29/206 (14.1%) for the entire cohort and was highest among patients 
with shock (0% vs. 6.1% vs 42.1%, p < 0.001). ICU admittance was 40/206 (23.8%), and half 
of shock cases needed ICU support (6.2% vs. 24.2% vs. 55.9%, p < 0.001). Mean LOS was 
13.1 ± 13,7 days, mean ICU LOS was 12,0 ± 12,2 days. 
Conclusions
In our pilot study among adult patients, CAS possessed significant disease burden and mor-
tality in severe cases. A dominant proportion of causative pathogens were susceptible, there-
fore a carbapenem-sparing approach might be favourable among these patients. More pro-
spective studies are warranted.
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Introduction
Acute bacterial foodborne diseases possess high morbidity in Europe. During recent years 
in Hungary, the incidence of campylobacteriosis exceeded the incidence of salmonellosis. 
Further data concerning species/serotype distribution and antibiotic susceptibility of entero-
pathogenic bacteria cultured from human stool samples are needed. Our aim was to analyze 
available microbiological data of consecutive adult patients presenting with clinical symp-
toms consistent with acute diarrhoea to assess these parameters. 
Methods
A secondary descriptive analysis of data extracted from a prospectively collected electronic 
database between January 1 and December 31, 2016 was carried out. All in- and outpatients 
were screened for eligibility by searching for appropriate admittance and discharge codes 
according to ICD-10 codes. Microbiological data of patients were included if acute diarrhoea 
was proven and stool samples were sent for microbiological culturing. Acute diarrhoea was 
defined as ≥3, Bristol 5-7 stools per ≤24 hours for 2–14 consecutive days. At our institution, 
fresh stool samples are screened for Salmonella, Campylobacter, Shigella and Yersinia sp. by 
routine culturing methods. Species identification is done by MALDI-TOF MS, antibiotic sus-
ceptibility testings and interpretation are executed according to current EUCAST guidelines. 
Results
Out of 4865 stool samples, 812 (16.7%) were culture positive. 516 (10.6%) samples grew 
Campylobacter sp. Among them, 413 (80.0%) were C. jejuni, 58 (11.2%) were C. coli, and 45 
(8.7%) were non-identifiable. 296 (6.1%) samples grew Salmonella sp., 154 (52.0%) were S. 
Enteritidis, 63 (21.3%) were S. non-Enteritidis and 79 (26.7%) were non-identifiable. Antibi-
otic susceptibility testing was done for 447 (86.6%) Campylobacter and 249 (84.1%) Salmo-
nella isolates. Most Campylobater strains were resistant to 1 or 2 types of tested antibiotics 
(42.1% and 41.6%), Salmonella isolates were dominantly susceptible to all examined antibi-
otics (67.5%). Among Campylobacter isolates, resistance to ciprofloxacin was exceptionally 
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high (83.4%), but virtually no erythromycin resistance was observed (0.6%). All Salmonella 
strains were susceptible to ceftriaxone, rates of ampicillin and ciprofloxacin resistance were 
similar (20.5% and 12.4%). However, S. non-Enteritidis isolates carried significantly higher 
rates of resistance to ampicillin (35.7% vs. 8.0%), trimethoprim/sulfamethoxazole (5.4% vs. 
0%) and ciprofloxacin (17.9% vs. 8.0%) compared to strains of S. Enteritidis. 
Conclusions
The positive detection rate of routine stool culturing was relatively low. The high rate of 
quinolone resistance among Camplyobacter isolates might be due to veterinary overuse of 
antibiotics. Community acquired acute diarrhoea should probably not be treated with fluoro-
quinolones empirically. Ceftriaxone may be a first drug for invasive Salmonella infections.
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